Medpace Holdings, Inc. MEDP Central Nervous System — Total Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Medpace Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Medpace Holdings, Inc.’s 10-Q, filed April 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Medpace Holdings, Inc.'s central nervous system — total revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Medpace Holdings, Inc.'s central nervous system — total revenue?
- Medpace Holdings, Inc. (MEDP) reported central nervous system — total revenue of $56.26M in Q1 2026.
- How has Medpace Holdings, Inc.'s central nervous system — total revenue changed year-over-year?
- Medpace Holdings, Inc.'s central nervous system — total revenue decreased by 3.5% year-over-year, from $58.28M to $56.26M.
- What is the long-term trend for Medpace Holdings, Inc.'s central nervous system — total revenue?
- Over 4 years (2021 to 2025), Medpace Holdings, Inc.'s central nervous system — total revenue has grown at a 18.9% compound annual growth rate (CAGR), from $119.69M to $239.37M.
- What does central nervous system — total revenue mean?
- The total revenue earned from providing clinical trial and drug development services for Central Nervous System therapeutic projects.
- How do you interpret central nervous system — total revenue?
- An increase indicates growing demand for the company's specialized neurological research services and successful project acquisition in the CNS therapeutic space, while a decrease may signal reduced client R&D spending or increased competition in this specific medical niche.
- How does central nervous system — total revenue compare across companies?
- Comparable to specialized therapeutic area revenue segments reported by other global contract research organizations (CROs) that break down performance by clinical indication or therapeutic focus.